Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Drug Evaluation × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Breast 4 Gastrointestinal 3 Lymphoid 2 Gynecologic 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Genitourinary 1 CNS 1

Conditions

Upper Tract Urothelial Carcinomas 1

Interventions

Docetaxel 376 pembrolizumab 292 Prednisone 266 enzalutamide 250 Magnetic Resonance Spectroscopy 245 Radiotherapy 242 Gemcitabine 242 Nivolumab 227 Abiraterone Acetate 193 Cisplatin 185 Radiosurgery 177 Leuprolide 177 Sunitinib 160 Carboplatin 146 Androgen Antagonists 137 Specimen Handling 136 bicalutamide 132 Goserelin 131 Paclitaxel 119 Ipilimumab 119 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 112 apalutamide 109 Cyclophosphamide 106 Sorafenib 101 Everolimus 101 cabozantinib 97 Biopsy 97 Bevacizumab 96 abiraterone 92 atezolizumab 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡